MDMA Proven Safe and Effective for PTSD in Dutch Report; EMA Releases Comprehensive Psychedelics Report |
|
Dutch Government Report on MDMA for PTSD |
|
In 2023, the Dutch Government established a State Committee on MDMA to examine its status in public health and provide recommendations on its medicinal use. This included a multidisciplinary analysis of health risks, prevention, the European context, and relevant treaties. The committee, composed of experts in international law, addiction, psychiatry, criminal law, emergency medicine, and prevention, presented a 233-page report to the Dutch Minister of Medical Care on June 6, 2024. Today, the full report was published in English. Key findings of the report include: - Harm from recreational ecstasy use in the Netherlands is limited, with no or very low dependence liability, no clinically relevant persistent cognitive deficits, and a limited number of serious incidents.
- MDMA-assisted therapy appears to be an effective and safe treatment for chronic and treatment-resistant PTSD patients.
- With approximately 400,000 people suffering from PTSD and less than 25% receiving evidence-based trauma treatment, there is a significant unmet need for PTSD treatment. The Dutch government should facilitate the introduction and use of MDMA-assisted therapy as soon as possible.
- Given the unlikely registration of this treatment with the European Medicines Agency soon, the committee proposes starting a large naturalistic study to provide MDMA treatment to those who need it most and to monitor PTSD patients receiving MDMA.
|
|
EMA published comprehensive report on psychedelics |
|
The European Medicines Agency has released a comprehensive report from its April multi-stakeholder workshop on psychedelics. Recently, the EMA has increased its focus on psychedelic therapies, resulting in several publications discussing the opportunities and challenges in this field. This report is the most extensive overview to date, summarizing discussions around several key themes: - Regulatory perspectives and developments
- Methodological challenges
- Safety considerations
- Considerations and challenges for implementation, including EU-specific issues such as Health Technology Assessment, funding opportunities, and compassionate use programs.
PAREA's contributions are extensively quoted in the report, particularly in discussions on legal classification. The report highlights an asymmetry in the drug scheduling system, where minimal anecdotal evidence can classify a substance as Schedule I, but extensive phase III clinical trial data is required for reconsideration. This scheduling adversely affects progress toward equitable access to psychedelic therapies. Key lessons and recommendations The workshop and report emphasize that despite specific challenges in developing psychedelic treatments, these can be mitigated through early engagement with regulators, HTA bodies, and payers. Cross-sector and multi-stakeholder collaboration is crucial for the development and safe rollout of these therapies. Healthcare systems need to build capacities similar to other medical fields, including standards of care and frameworks for psychological support. The report also mentions PAREA's recommendation to create a pan-European multidisciplinary advisory body to provide a comprehensive framework for addressing mental health innovation in the EU. This body could recommend care models for psychedelics, training and licensing standards, ethical guidelines, and safety standards. |
|
PAREA c/o Drug Science UK, 2 Langley Lane
London, SW8 1GB, UK |
|
|
|
